Objective: To study the effect of the intake of 15 g nondigestible oligosaccharides per day on various parameters of large-bowel function, as well as on blood lipid concentrations and glucose absorption in man. Design: Latin square, randomized, double-blind, diet-controlled. Setting: Metabolic research unit. Subjects: Twelve apparently healthy men (mean age 23 years), recruited from the Institute's pool of volunteers, no drop-outs. Interventions: Four treatment periods of 3 weeks: inulin, fructo-oligosaccharides (FOS), galacto-oligosaccharides (GOS) and control; analyses of stool weight, intestinal transit, faecal pH, short-chain fatty acids, bile acids, faecal enzymes, blood lipids and glucose absorption. Results: As compared to the control treatment: higher concentration of faecal acetate (inulin and GOS, P`0.05) and valerate (inulin, P`0.05), signi®cantly lower concentration of faecal deoxycholic acid (inulin and FOS, P`0.05 and P`0.02, respectively) and b-glucuronidase activity (inulin and GOS, P`0.05 and P`0.02 respectively). Other changes of faecal parameters and those of blood lipids and glucose absorption were statistically not signi®cant. Conclusions: Results indicate that nondigestible oligosaccharides are (partly) fermented in the human colon, but in healthy young men the effects are limited. Also the consumption of 15 g nondigestible oligosaccharides does not seem to alter blood lipid concentrations and glucose absorption in our young healthy adults.
Introduction
Nondigestible oligosaccharides (NDO) are carbohydrates that escape digestionahydrolysis in the stomach and small intestine, but they are (partly) fermented by the colonic bacterial¯ora. These oligosaccharides may consist of one moiety of glucose to which, on average, 2 to $ 10 fructosyl, galactosyl or other carbohydrate monomers are bound by a b-bond. Fructo-oligosaccharides are present in large amounts in inulin, extracted, for example, from the chicory root, and are present in leek and onions. Galactooligosaccharides may be found in soybeans and can be synthesised from lactose.
Mostly on the basis of animal experiments, it can be concluded that the effects of NDO are comparable with those of dietary ®bre, which means a potential in¯uence on colonic fermentation, with a number of primary and secondary effects on blood lipid concentrations, glucose absorption and mineral utilisation. Generally these effects are evaluated as bene®cial for human health. A review by Roberfroid (1993) summarises the ®ndings and hypotheses. Not many experiments in man have been published, so we have investigated in healthy subjects the extent to which oligosaccharides may in¯uence human physiology. The overall objective of the study was to evaluate possible health-promoting effects when NDO are incorporated in the daily diet of man.
In this paper results of the in¯uence of NDO on a number of bowel function and faecal parameters are presented, as well as on blood lipid concentrations and glucose absorption. Results with respect to mineral absorption have been reported elsewhere (van den Heuvel et al, 1998) .
Methods

Subjects
One group of 12 healthy male subjects was selected for the study. Their mean age was 23 (SD 3) years, body weight was 79.8 (SD 9.2) kg and height was 186 (SD 6) cm. They had to be used to an average Dutch diet and to have normal bowel habits. Normal health was assessed during pre-study screening, including a medical history, physical examination, vital signs and clinical laboratory tests. Habitual dietary intake was assessed by questionnaires. The study protocol was approved by the TNO Medical-Ethics Committee and subjects signed informed consent forms, according to EEC guidelines and TNO routine procedures.
Experimental design
The study consisted of four experimental periods of 21 days. During all periods the subjects consumed a constant and controlled basal diet. During each period this diet was supplemented with 15 g of inulin, fructo-oligosaccharides, galacto-oligosaccharides or no added NDO. The study design was set up according to three Latin squares; the 12 subjects were randomly assigned to one of the treatment orders. The study was carried out`double-blind'.
During the ®rst 14 days of each period the subjects lived in their own environment, but they had to consume dinner in the Institute's metabolic ward; other meals and snacksadrinks could be consumed elsewhere. During the last 7 days of each period they stayed in the metabolic ward and all foods had to be consumed there. All measurements, tests and analyses took place during each last 7 days of the 3-week treatment period.
Food intake and intake of NDO During the entire period of 84 days the basal diet (without NDO) consisted of normal food products, conforming to a habitual Dutch food pattern and close to the average consumption pattern of the subjects' age category, according to the results of the National Food Consumption Survey 1991 ± 1992 (Nutrition Educational Board, 1993 . The composition of the various food products was constant; to this end, foods were purchased from one batch. Preparation, storage and distribution of the foods, meals and snacks were executed according to standard procedures of the TNO institute. The energy content and nutrient composition of the basal diet, based on chemical analysis according to standard methods (dietary ®bre by a modi®ed AOAC method, Prosky et al, 1988 ) is given in Table 1. Table 2 presents an example of the daily menu.
In addition to the basal diet, different types of NDO were provided in orange juice during breakfast, lunch and dinner (the cooked meal). The subjects were instructed about the quantitative intake of the orange juice in order to ensure that all NDO provided were consumed. The daily intake of NDO (inulin, fructo-oligosaccharides or galactooligosaccharides) was constant (15 gaday) and evenly divided over the three meals. As the pure oligosaccharide content of the supplements was not 100%, the weight of the individual NDO was adjusted for a constant intake of 15 g of pure oligosaccharides.
The individual daily energy intake was based on maintaining a constant body weight. Body weight loss of more than 2% of the initial weight at the start of the experiment was corrected by providing either soft drinks andaor products with a high (available) carbohydrate content. Table 3 shows some characteristics of the NDO supplements.
Bowel function and faecal parameters
During the last 7 days of each treatment period of 21 days the effect of NDO on bowel function and faecal parameters was measured as follows: (a) subjective evaluation of gastrointestinal complaints (questionnaire about the previous 7 days); (b) intestinal transit time by radio-opaque markers (Hinton et al, 1969; Cummings et al, 1976) ; (c) amount of hydrogen in expired air for measuring the rate of fermentation (Lactoscreen H 2 breath tester, Hoekloos, Amsterdam, The Netherlands).
In a homogenised 48-h faecal sample at the end of each treatment period the following analyses were carried out: (1) faecal pH using a pH electrode as described by van Faassen et al (1993) ; (2) concentration and composition of faecal short-chain fatty acids (by HPLC); (3) concentration and composition of faecal bile acids and neutral steroids (by GLC); (4) faecal enzyme activity (various methods, see below).
For faecal collections, the subjects used a deep-freeze toilet with a plastic bag inside (Ghoos and van Trappen, 1977) . Daily collections were made and the bags were properly labelled and stored at 7 20 C. For sample preparation, approximately 25 g of the 48-h homogenised faecal sample was thawed at room temperature and a known amount of water was added and the sample was homogenised with a Waring commercial blender (Model 32BL79, New Hartford, CT, USA) and The concentrations of bile acids (lithocholic acid, deoxycholic acid, chenodeoxycholic acid, cholic acid, isolithocholic acid) and steroids (campesterol, coprostanol, cholesterol, stigmasterol, b-sitosterol) were analysed according to Child et al (1987) . The lipids were extracted using a mixture of trichloromethane ± methanol (2:1). The butyl ester-acetate derivatives were prepared according to Marai & Kuksis et al (1982) . From the ®nal dried extract, which was taken up in trichloromethane, 1 ml was injected into the gas chromatograph. Chromatographic separations were done on a Carlo Erba gas chromatograph (HRGC 5300) mounted with an auto-sampling injector and ®tted with a¯ame ionisation detector and split injector. A 30 m DB-5 capillary column with internal diameter of 0.319 mm and ®lm thickness of 1.0 mm (J&W Scienti®c, Folsom, CA, USA) was used. Both the injector and detector temperatures were kept at 300 C. The carrier gas was helium at a head pressure of 100 kPa and the split ratio was 18.7 mlamin. The temperature program was as follows: injections were made at 50 C; the oven temperature was increased to 200 C at the rate of 30 Camin, and further to 285 C at 4
Camin, and ®nally to 310 C at 2 Camin and kept at this temperature for 40 min. Retention times and peak areas were computed using Maximaabaseline software (Millipore Corporation, MA, USA).
For assaying faecal enzyme activities (b-glucuronidase, b-glucosidase, urease and tryptophanase), approximately 2 g of homogenized faecal samples were taken in liquid nitrogen and disrupted in Te¯on pots for 5 min at an amplitude of 1 cm in a micro-dismemberator (B. Braun Melsungen AG, Germany). The following procedures were all done at 4
C. Approximately 1 ± 1.5 g disrupted faeces was added to 15 ml of 0.1 molal phosphate-buffered saline (PBS, pH 6.5) and mixed using a vortex mixer for 1 min; this enzyme extract was used for assaying b-glucuronidase, b-glucosidase and urease activity. For assaying tryptophanase activity, 2 ml of cold acetone was added to 1 ml of a faecal suspension taken in 0.05 molal PBS (pH 7) which was mixed in a vortex mixer, and centrifuged at 1700 g for 10 min at 4 C; the supernatant (enzyme extract) was used for measuring enzyme activity. All enzyme activities were measured spectrophotometrically and performed in triplicate. b-Glucuronidase activity was assayed according to Goldin et al (1980) . This procedure was also applied for bglucosidase. Urease activity was measured using a reagent kit purchased from Boehringer Mannheim Germany (cat. no. 542946). Tryptophanase was measured spectrophotometrically at 540 nm (LKB Ultraspec K 4053). Although freezing might have affected relative enzyme activities, possibly leading to lower levels, the most important question was to observe whether administration of NDO might affect enzyme activities, thus the differences between treatments were more important than the absolute values. Because the various analyses were carried out at the end of the whole study (for practical reasons, but also to avoid day-to-day variation of equipment used), we checked whether storage time might have in¯uenced the enzymatic data. As each experimental period of 21 days covered all treatments (the same treatment for each 3 subjects), we calculated the enzyme activities for each (chronological) period of 21 days and analysed the data statistically. Table  4 presents the results and it appears that no statistically signi®cant differences could be observed between the (chronological) periods of 21 days for all assayed enzyme activities.
Short-chain fatty acids (lactate, acetate, propionate, butyrate, valerate and a few branched-chain acids) were determined by HPLC, using the Bio-Rad column system Aminex HPX-87H.
Blood sampling and analyses
At the end of each treatment period of 3 weeks, blood was sampled after an overnight fast on two consecutive days for determination of blood lipid concentrations. Total serum cholesterol was analysed by the CHOD-PAP method (Hitachi-911 analyser, Boehringer reagent, Boehringer Mannheim, Germany); total HDL-cholesterol and HDL3-cholesterol were determined by the CHOD-PAP precipitation method (Boehringer, Mannheim); and HDL2-cholesterol was calculated as the difference between total HDL-cholesterol and HDL3-cholesterol.
LDL cholesterol was calculated by using the Friedewald equation (Friedewald et al, 1972) . Total phospholipids were analysed by the molybdate reaction method (Hitachi 717 system pack, Boehringer reagent, Boehringer Mannheim) and triacylglycerol enzymatically (Hitachi 911 analyser, Boehringer reagents). Apolipoprotein (apo)A-1 and apoB were measured by the Hitachi 911 analyser using an immunoturbidimetric test method (Boehringer Mannheim).
The in¯uence of NDO on glucose absorption and insulin response was evaluated with a classical glucose tolerance test, executed in the last week of each treatment period of 3 weeks.
After an overnight fast of 10 h, the subjects were given a glucose test solution (50 g of glucose) with 5 g of one of the NDO or no NDO (control). Blood was sampled at ®ve time points (before ingestion of the test solution and 30, 60 90 and 120 min after ingestion of the test solution). Glucose was determined by the hexokinase method on the Hitachi 911 (reagents Boehringer Mannheim) and insulin by a twosite immunoenzymmometric method (AIA-600 immuno assay analyser, TOSOH, Japan). None of the differences between periods reached statistically signi®cant levels (P b 0.05).
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Data processing and statistical analysis
The various analytical data were processed and analysed statistically according to standard methods of the TNO institute. Analysis of variance with block structure was applied to detect differences between treatments, according to the experimental design. For some parameters showing a nonsymmetric distribution, a log transformation was made. Differences were considered statistically signi®cant at P`0.05.
Results
The study could be carried out without serious problems. All 12 subjects completed the study and they remained in good health throughout the whole period of 84 days. Mean body weight did not change considerably (initial mean weight 79.8 kg; after three weeks 79.1 kg; after 84 days 78.1 kg). The consumption of orange juice (with or without NDO) did not cause problems. Generally, consumption of the 15 g NDO per day did not increase gastrointestinal complaints considerably; most subjects reported only more cases of¯atulence. As some complaints were also recorded on the control diet (the study was executed`double-blind'), the conclusion is that the 15 g of NDO per day was well tolerated by our subjects. Table 5 shows the results of faecal weight and transit time. Almost none of the differences observed were statistically signi®cant. Only a signi®cant lower percentage of faecal dry weight was measured during the GOS period as compared with the control period (P`0.05). After log transformation, for both inulin and GOS, faecal wet weight was signi®cantly higher than that for FOS (P`0.05).
Most parameters of large-bowel function did not show statistically signi®cant differences between treatments (see Table 5 ). Also, most concentrations of short-chain fatty acids (see table 6) did not change signi®cantly on the intake of NDO, although the concentration of the predominant acid (acetic acid) was signi®cantly higher during both the inulin and GOS treatment as compared with the control period (P`0.05). For valeric acid the concentration was signi®cantly higher during the inulin treatment when compared with the control period (P`0.05). After log transformation, the concentration of isobutyric acid was signi®cantly higher during the inulin period than during the control period (P`0.02). Figure 1 shows the results for hydrogen production in expired air. The overall hydrogen production in 240 min was signi®cantly larger on the FOS diet than on the control diet (P`0.05). Table 7 presents the results for bile acids. In both the inulin and the FOS periods the concentration of deoxycholic acid (one of the secondary bile acids) was signi®-cantly lower than in the control period (P`0.05 and P`0.02, respectively). No signi®cant differences were observed for the concentration (see Table 8 ) and excretion Mean transit time of all 20 radio-opaque pellets swallowed. *Signi®cantly lower than the control period (P`0.05). 
Values are mean (s.d.) (n 12). a Acids are expressed as mga100 g dry faeces. *Signi®cantly higher than the control treatment (P`0.05). 
Effects of nondigestible oligosaccharides W van Dokkum et al
(results not shown) of faecal neutral steroids. Table 9 shows the activities of four faecal enzymes. After log-transformation, the b-glucuronidase activity during both the inulin and GOS periods was signi®cantly lower than during the control period (P`0.05 and P`0.02, respectively).
Results of the analysis of blood lipids concentrations are presented in Table 10 . Data are the means of the concentrations in blood sampled on two consecutive days at the end of each treatment period. From this table it appears that the slight differences between treatments did not reach statistical signi®cance.
Results of the glucose tolerance test are shown in Figures 2 and 3 . For this test also the differences observed between treatments were not statistically signi®cant.
Discussion
This study on the short-term effects of non-digestible oligosaccharides (NDO) on human physiology was designed to investigate whether consumption of 15 g of NDO per day could alter the levels of various physiological parameters in young healthy male subjects within 3 weeks. The amount of 15 gad was chosen as this level of NDO consumption can be envisaged when NDO-containing foods appear on the market.
Because the study was executed`double-blind', it was possible to observe subjective gastrointestinal complaints (if any) possibly caused by the intake of NDO. In addition, it was possible to check whether the consumption of NDO with orange juice as vehicle was tolerated by our subjects. Through observation of the subjects and via questionnaires it is concluded that gastrointestinal complaints were not much different from those normally observed and that amounts of NDO up to 15 g are well tolerated.
In designing the study it was envisaged that consuming NDO could have resulted in clearer changes of the (physiological) parameters studied than in fact was found. These expectations were based partly on results of animal studies and partly on the knowledge of effects of dietary ®bre on human physiology (for details see the paper of Roberfroid, 1993) . Steroids are expressed as mgag dry faeces. None of the differences reached statistically signi®cant levels (P b 0.05). (431) 191 (107) 1136 (593) Values are mean (s.d.) (n 12). None of the differences reached statistically signi®cant levels (P b 0.05). 
Effects of nondigestible oligosaccharides W van Dokkum et al
One of the reasons for limited changes in bowel function and faecal parameters is accounted for by the relatively high dietary ®bre content (24 gaday) of the control diet (although this ®bre intake is the habitual intake of our subjects and so a realistic amount) and the fact that our subjects were young adults, which may raise the question whether an apparently`healthy' colon can become more healthy on the consumption of NDO. Nevertheless, from the observed changes of the levels of several parameters (such as hydrogen production, short-chain fatty acids) it can be concluded that NDO are fermented by the colonic bacterial¯ora but that the effects are indeed limited. One of the known drawbacks of analysing faecal samples is the fact that they do not necessarily represent quantitatively what happens in different parts of the colon. For example, the short-chain fatty acids are predominantly produced and absorbed in the proximal colon, where metabolic activity of the bacterial¯ora is higher than in the distal colon (Gibson & Roberfroid, 1995) . The amount of acids recovered in the faeces is thus a small percentage of the amount produced. A small effect in faecal samples could therefore mean a large effect in the proximal colon.
Because of the limited effects observed in our study, the signi®cance of the ®ndings for human health is only summarized below rather than discussed in detail. Also, in a recent paper by Alles et al (1996) , effects of the intake of 5 g and 15 g of fructo-oligosaccharides per day on various parameters of large intestinal function were very limited.
It is well documented that fermentation of carbohydrates that escape digestion in the stomach and small intestine exerts a number of effects that are supposed to be bene®cial for (colonic) health, including an increase in stool volume, a shorter intestinal transit time, production of short-chain fatty acids and a decrease of colonic pH (Kritchevsky, 1988) . This was partly con®rmed in our study for NDO.
It has been suggested that the composition of bile acids in the colon and the activity of faecal enzymes play a role in the pathogenesis of colon cancer (Reddy et al, 1992) . Generally, a decrease of faecal enzyme activities (including b-glucuronidase, b-glucosidase and urease) and a decrease of the concentration of secondary bile acids (lithocholic acid and deoxycholic acid) could reduce the risk for developing cancer of the colon (Goldin & Gorbach, 1984; Reddy et al, 1987) . The signi®cantly lower concentration of faecal deoxycholic acid during the inulin and FOS periods and the signi®cantly lower activity of faecal b-glucuronidase on the inulin and GOS treatments in our study is an indication of a positive effect of the consumption of NDO. Jenkins et al (1975) originally observed a hypocholesterolaemic effect of guar gum, a water soluble noncellulosic polysaccharide. Since then, many studies have con®rmed that guar gum can reduce total cholesterol and LDL concentrations in normal subjects (Smith and Holm, 1982; Penagini et al, 1986) and in hyperlipidaemic subjects (Wirth et al, 1982; Aro et al, 1984) . Also, soluble ®bre in oats, rye and barley has been shown to reduce serum cholesterol concentrations, although high quantities of those products are needed for signi®cant effects (van Horn et al, 1986; Turnbull & Leeds, 1987) . Regarding possible mechanisms of the hypocholesterolaemic effect of soluble ®bre, the following hypotheses have been suggested: (1) in¯uence on bile acid absorption and metabolism (reduction of the body pool of cholesterol by increase of faecal bile acid excretion (Anderson et al, 1984) ); (2) and in¯uence through the effect on the formation of shortchain fatty acids (these acids may inhibit cholesterol synthesis in the liver (Chen & Anderson, 1986) ).
Both of these hypotheses are also applicable for nondigestible oligosaccharides, for which fermentation in the colon causes similar effects to those documented for (soluble) ®bre (Roberfroid, 1993) . In our study, however, the cholesterol-lowering effect of NDO was not observed, which can partly be accounted for by the fact that the initial serum cholesterol concentrations in our young healthy adults were already low. Lund et al (1990) showed that the cholesterol-lowering effect of oat bran diminishes with decreasing initial plasma cholesterol concentration. Moreover, effects have been observed by giving much higher quantities of ®bre than the 15 g NDO per day that we provided, which is a more realistic quantity from a practical and applied point of view. In a recent non-diet-controlled study with 64 young healthy females who were given 14 g inulin per day for 4 weeks, again no signi®cant effects on blood lipid concentrations were observed (van Amelsvoort et al, 1996) . In diabetic patients, oligofructose intake of 8 ± 10 g per day for 2 to 16 weeks caused a decrease in serum total cholesterol and LDL-cholesterol concentrations (Yamashita et al, 1984) . Similar effects were observed in hyperlipidaemic patients (Hata et al, 1983) .
The importance of diet in the treatment of diabetics has been recognised for a considerable time. Dietary management of diabetes includes the aim of maintaining blood glucose concentration at normal levels. In particular, diets rich in soluble ®bre (from beans and legumes) have an effect on post-prandial blood glucose concentrations (Fuessl et al, 1987) . The effect of ®bre can partly be accounted for by its slow-release capacity and the reduction of the rate of digestion of carbohydrates and of absorption of glucose (British Nutrition Foundation, 1990) . High levels of ®bre intake were used to provide signi®cant effects, (Monnier et al, 1981; Simpson et al, 1981) . However, more realistic levels of ®bre intake (approximately 40 g per day) also caused small but signi®cant effects on post-prandial blood glucose concentrations in non-insulindependent diabetes mellitus (Karlstrom et al, 1984) . Some studies indicate that in diabetic subjects the intake of oligofructose leads to a decrease in fasting blood glucose concentrations (Yamashita et al, 1984) .
In our study we did not observe the slow-release capacity of NDO at the levels of intake that were applied. This could be because our subjects were healthy and non- 
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W van Dokkum et al diabetics. In summary, it seems that the application of nondigestible oligosaccharides in food products in quantities up to 15 gaday does not involve an extra health effect regarding the reduction of blood lipid concentrations or glucose absorption in healthy individuals. The bene®cial signi®cance of NDO is probably more apparent in terms of fermentation of NDO in the colon and its subsequent primary and secondary effects. On the other hand, it should not be excluded that NDO may be bene®cial for people with elevated blood lipid concentrations and for diabetic patients. However, the magnitude of any effect should not be overestimated.
